Clinical trials
Epstein-Barr Virus (EBV) Infection clinical trials
Below are recruiting epstein-barr virus (ebv) infection clinical trials, each written for real people, not researchers. We’re tracking 25 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07450391RecruitingPhase 1/Phase 2
EBV-targeted cell therapy for EBV-related lymph disorders
This trial tests an experimental cell therapy that targets cells infected with the Epstein-Barr virus (EBV). It is for patients with certain blood cancers or post-transplant lymph disorders caused by EBV that have not responded to standard treatments or who cannot receive them.
Beijing, Beijing MunicipalityAges 18–70 - NCT07693881Recruiting
Preventing EBV reactivation with rituximab after stem cell transplant in children
This trial tests whether adding a drug called rituximab to the standard transplant plan can help prevent Epstein-Barr virus (EBV) from reactivating in children receiving a half-matched stem cell transplant. It may help reduce a common viral complication after transplant.
GuangzhouAges Up to 18 years - NCT07381738RecruitingPhase 2
Cord blood transplant for Epstein-Barr virus diseases
This trial uses donated umbilical cord blood (a type of stem cell transplant) to treat people with serious illnesses caused by the Epstein-Barr virus. It's an option for those whose disease has not responded to other treatments.
Shanghai, Shanghai MunicipalityAges 14–80 - NCT05934448RecruitingPhase 2
CAR T plus pembrolizumab for relapsed lymphoma after prior treatment
This Phase 2 trial studies CAR T-cell therapy combined with pembrolizumab for certain hard-to-treat lymphomas that have come back or did not respond. It aims to improve tumor response and outcomes after you’ve already tried standard treatments.
Boston, MassachusettsAges 18 years+ - NCT06926894RecruitingPhase 1
A cell therapy for viral infections in children and young adults
This trial tests a special immune cell treatment (R-MVST cells) for children and young adults who have had a stem cell or organ transplant and are fighting stubborn viral infections like EBV, CMV, ADV, or BK virus. The goal is to see if these cells can help control the viruses when standard medicines haven't worked well enough.
New York, New YorkAges 3 months–26 years - NCT03266653RecruitingPhase 2
T-cell therapy for stubborn Epstein-Barr virus after transplants
This trial tests an immune therapy made from EBV-targeted T-cells to treat EBV infections that do not improve with standard anti-viral medicines. It may help by strengthening the body’s ability to fight EBV after certain transplants or immune problems.
Los Angeles, CaliforniaAges 1 month–79 years - NCT05957913Enrolling by invitationPhase 2
Testing antiviral drugs to control Epstein-Barr virus in MS
This Phase 2 study tests whether certain antiviral medicines can reduce Epstein-Barr virus (EBV) activity. If you have multiple sclerosis and evidence of EBV infection, the results may help clarify new ways to target EBV-related disease activity.
Boston, MassachusettsAges 18 years+ - NCT04308278RecruitingPhase 4
Test two supplements for long fatigue from EBV infection
This trial studies whether two products (2LEBV® and 2LXFS®) can improve ongoing fatigue in people who have evidence of an Epstein-Barr virus (EBV) infection. It aims to see if treatment helps reduce multiple related symptoms over follow-up.
AartselaarAges 12 years+ - NCT04989491RecruitingPhase 4
Single-dose rituximab to prevent EBV after kidney transplant
This trial tests whether one dose of rituximab (given around the time of transplant) can help prevent a first Epstein-Barr virus (EBV) infection and related abnormal lymph node or immune growths after kidney transplant. It is specifically for adults who are EBV-negative before receiving an EBV-positive donor kidney.
StrasbourgAges 18 years+ - NCT05127980Recruiting
Study of immune antibodies after first-time EBV infection
This study looks at how the immune system’s antibodies behave after a first-time EBV infection, including whether they mistakenly react with the body’s own tissues. You might be offered a chance to help doctors understand why some people get longer or more intense symptoms from infectious mononucleosis.
BaselAges 18 years+ - NCT05183490RecruitingPhase 1
Cell therapy for repeated viral infections after transplant
This early-phase (Phase 1) study tests an immune cell treatment (R-MVST) to help people whose immune system has been weakened by a past transplant and who keep getting viral infections reactivated or not responding well to standard treatment. It may help your body control viruses like EBV, CMV, adenovirus, or BK virus.
New York, New YorkAges 18 years+ - NCT05978141Recruiting
T-cell lymphoma registry study
This study creates a registry for people with certain T-cell or NK-cell lymphomas. It collects health information and tumor samples to learn more about these diseases and improve future treatments.
Duarte, CaliforniaAges Any age - NCT06224049RecruitingEarly Phase 1
New immune cells for Epstein-Barr virus positive T-cell lymphoma
This trial tests a new treatment using specially designed immune cells (called hNeo-T cells) to attack Epstein-Barr virus positive T-cell lymphoma that has come back or not responded to standard therapy. The treatment is personalized based on your tumor's unique markers and your tissue type (HLA).
Shenzhen, GuangdongAges 18–75 - NCT06592599RecruitingPhase 2
Drug combo for EBV-related nasopharyngeal cancer
This trial tests a combination of three drugs (gemcitabine, docetaxel, and toripalimab) as a first treatment for a type of nasopharyngeal cancer linked to the Epstein-Barr virus. The goal is to see if this combination helps shrink tumors before other treatments like radiation.
Palo Alto, CaliforniaAges 18 years+ - NCT06789159RecruitingPhase 1
VK-2019 for relapsed/refractory EBV-positive DLBCL
This trial tests a new drug called VK-2019 for people whose EBV-positive diffuse large B-cell lymphoma has come back or not responded to at least two prior treatments. The goal is to see if this drug can shrink tumors and help control the cancer.
Lexington, KentuckyAges 18 years+ - NCT06908096RecruitingPhase 1
EBV nanoparticle vaccine study for healthy adults
This study tests two experimental vaccines against Epstein-Barr virus (EBV), the germ that causes mono. You may be able to join if you are a healthy adult aged 18–29 and haven't had an EBV vaccine before. The trial will check if the vaccines are safe and trigger an immune response.
Bethesda, MarylandAges 18–29 - NCT06909110RecruitingPhase 1/Phase 2
Immune cells for viral infections after transplant
This trial tests a treatment using specially trained immune cells (virus-specific T-cells) to fight stubborn infections with adenovirus, CMV, or EBV in people with weakened immune systems, such as after a stem cell or organ transplant.
Palo Alto, CaliforniaAges 1 month–65 years - NCT06741072RecruitingPhase 1
Vaccine to prevent EBV-related cancer in transplant patients
This trial tests a vaccine (OSU-2131) that may help prevent cancers caused by the Epstein-Barr virus in people waiting for an organ transplant. The vaccine is designed to train your immune system to fight the virus.
Columbus, OhioAges 18–65 - NCT07306156RecruitingPhase 1/Phase 2
GP350 CAR-T for Epstein-Barr virus related lymphoma
This trial tests a new treatment called GP350 CAR-T for patients with lymphoma (a type of blood cancer) that has come back or not responded to standard therapy, especially when linked to Epstein-Barr virus (EBV) infection. The therapy uses your own immune cells, modified to target and kill cancer cells carrying the GP350 protein from EBV.
Hefei, AnhuiAges 18–70 - NCT07368634RecruitingPhase 1/Phase 2
EBV-TCR-T cells for persistent EBV after stem cell transplant
This trial tests whether special immune cells (called EBV-TCR-T cells) can help clear the Epstein-Barr virus in people who still have high virus levels after a stem cell transplant. It's an experimental therapy for those whose virus hasn't responded to standard care.
BeijingAges 18–70 - NCT00032513Recruiting
Genetic study of chronic active Epstein-Barr virus disease
This research study looks for genetic factors that may explain why some people develop severe, long-lasting Epstein-Barr virus (EBV) infection. Researchers will study blood and tissue samples from patients with this rare condition, their healthy relatives, and unrelated volunteers to understand the disease better.
Bethesda, MarylandAges 1–120 - NCT03258567RecruitingPhase 2
Nivolumab for EBV-related lymphomas and abnormal immune illnesses
This trial tests nivolumab (an immune therapy) for people with EBV-positive lymphoma or EBV-driven immune/lymph conditions. It may help shrink tumors or control the disease when standard treatments have not worked or are not suitable.
Bethesda, MarylandAges 12 years+ - NCT06689397Enrolling by invitation
Study of Epstein-Barr virus-related pink eye
This trial is studying a specific type of eye infection (pink eye) caused by the Epstein-Barr virus. It aims to better understand the condition and may help guide treatment for people with these symptoms.
LondonAges 16 years+ - NCT06027879Enrolling by invitationPhase 1/Phase 2
Anti-viral T-cell therapy for stubborn viral infections after transplant
This trial tests a treatment using specially grown T-cells (a type of immune cell) to fight certain viruses that won't go away with standard medicines. It is for people who have had a stem cell or organ transplant, or who have a weak immune system, and who are struggling with adenovirus, CMV, or EBV infections.
Pittsburgh, PennsylvaniaAges 1 month–65 years
Hear when a new Epstein-Barr Virus (EBV) Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for epstein-barr virus (ebv) infection?
- Yes. Clin2 currently lists 25 recruiting epstein-barr virus (ebv) infection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a epstein-barr virus (ebv) infection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a epstein-barr virus (ebv) infection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.